Most Recent Peer-Reviewed Publication
Behzadi MA, Choi A, Duehr J, Feyznezhad R, Upadhyay C, Schotsaert M, Palese P, Nachbagauer R. A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro. Sci Rep. 2020;10(1):9750. Published 2020 Jun 16. doi:10.1038/s41598-020-66600-x. PMID:32546721
Zheng A, Sun W, Xiong X, Freyn AW, Peukes J, Stromeier S, Nachbagauer R, Briggs JAG, Krammer F, Palese P. Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals [published online ahead of print, 2020 Jun 3]. J Virol. 2020;JVI.00742-20. doi:10.1128/JVI.00742-20
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol Ther. 2020 Apr 19:S1525-0016(20)30199-4. doi: 10.1016/j.ymthe.2020.04.018. Online ahead of print.PMID: 32359470
Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. Lancet. 2020 Mar 7;395(10226):e42-e43. doi: 10.1016/S0140-6736(20)30418-9. Epub 2020 Feb 19.PMID: 32087122
High-complexity extracellular barcoding using a viral hemagglutinin. Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2767-2769. doi: 10.1073/pnas.1919182117. Epub 2020 Jan 27.PMID: 31988118
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. NPJ Vaccines. 2019 Dec 6;4:51. doi: 10.1038/s41541-019-0147-z. eCollection 2019.PMID: 31839997
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. J Virol. 2020 Jan 17;94(3):e01677-19. doi: 10.1128/JVI.01677-19. Print 2020 Jan 17.PMID: 31694938
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine. 2019 Nov;49:96-105. doi: 10.1016/j.ebiom.2019.10.032. Epub 2019 Oct 29.PMID: 31676387
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020 Jan;20(1):80-91. doi: 10.1016/S1473-3099(19)30393-7. Epub 2019 Oct 17.PMID: 31630990
Nachbagauer R, Palese P. Is a Universal Influenza Virus Vaccine Possible. Annu Rev Med. 2019 Oct 10. doi: 10.1146/annurev-med-120617-041310. [Epub ahead of print] PubMed PMID: 31600454.